NCT00494091 - Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

March 31, 2012

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG

Temsirolimus (CCI-779)

20 mg/m2 IV TEMSR weekly (Japan, n=6)

DRUG

Temsirolimus (CCI-779)

25 mg IV TEMSR weekly (all other pts)

Trial Locations (24)

100021

Pfizer Investigational Site, Beijing

100036

Pfizer Investigational Site, Beijing

100730

Pfizer Investigational Site, Beijing

200032

Pfizer Investigational Site, Shanghai

200127

Pfizer Investigational Site, Shanghai

210002

Pfizer Investigational Site, Nanjing

Unknown

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Gunma

Pfizer Investigational Site, Hokkaido

Pfizer Investigational Site, Ibaraki

Pfizer Investigational Site, Kagawa

Pfizer Investigational Site, Kagoshima

Pfizer Investigational Site, Kyoto

Pfizer Investigational Site, Nara

Pfizer Investigational Site, Okayama

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Shizuoka

Pfizer Investigational Site, Tokyo

Pfizer Investigational Site, Yamagata

110-744

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

135 710

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul